Department of Medicine, Divisions of Hematology and Oncology, Stanford University Medical Center, Stanford, California.
Aix-Marseille University, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Marseille, France.
Cancer Discov. 2023 Jun 2;13(6):1310-1323. doi: 10.1158/2159-8290.CD-23-0111.
Follicular lymphomas (FL) are characterized by BCL2 translocations, often detectable in blood years before FL diagnosis, but also observed in aging healthy individuals, suggesting additional lesions are required for lymphomagenesis. We directly characterized early cooperating mutations by ultradeep sequencing of prediagnostic blood and tissue specimens from 48 subjects who ultimately developed FL. Strikingly, CREBBP lysine acetyltransferase (KAT) domain mutations were the most commonly observed precursor lesions, and largely distinguished patients developing FL (14/48, 29%) from healthy adults with or without detected BCL2 rearrangements (0/13, P = 0.03 and 0/20, P = 0.007, respectively). CREBBP variants were detectable a median of 5.8 years before FL diagnosis, were clonally selected in FL tumors, and appeared restricted to the committed B-cell lineage. These results suggest that mutations affecting the CREBBP KAT domain are common lesions in FL cancer precursor cells (CPC), with the potential for discriminating subjects at risk of developing FL or monitoring residual disease.
Our study provides direct evidence for recurrent genetic aberrations preceding FL diagnosis, revealing the combination of BCL2 translocation with CREBBP KAT domain mutations as characteristic committed lesions of FL CPCs. Such prediagnostic mutations are detectable years before clinical diagnosis and may help discriminate individuals at risk for lymphoma development. This article is highlighted in the In This Issue feature, p. 1275.
滤泡性淋巴瘤 (FL) 的特征是 BCL2 易位,通常在 FL 诊断前数年即可在血液中检测到,但也可见于衰老的健康个体中,这表明淋巴发生还需要其他病变。我们通过对 48 名最终发展为 FL 的患者的预诊断血液和组织标本进行超深度测序,直接对早期协同突变进行了特征分析。引人注目的是,CREBBP 赖氨酸乙酰转移酶 (KAT) 结构域突变是最常见的前体病变,并且在很大程度上区分了患有 FL 的患者(14/48,29%)与有或无检测到 BCL2 重排的健康成年人(0/13,P = 0.03 和 0/20,P = 0.007)。CREBBP 变体在 FL 诊断前中位时间为 5.8 年即可检测到,在 FL 肿瘤中克隆选择,并似乎仅限于定型 B 细胞谱系。这些结果表明,影响 CREBBP KAT 结构域的突变是 FL 癌前细胞 (CPC) 中的常见病变,具有区分有发展为 FL 风险的患者或监测残留疾病的潜力。
我们的研究为 FL 诊断前的反复遗传异常提供了直接证据,揭示了 BCL2 易位与 CREBBP KAT 结构域突变的组合作为 FL CPC 的特征性定型病变。这些预诊断突变在临床诊断前数年即可检测到,可能有助于区分有患淋巴瘤风险的个体。本文在本期特色文章中重点介绍,第 1275 页。